- Surface Oncology SURF has announced new data from the ongoing Phase 1 studies of SRF388 and SRF617.
- SRF388 data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.
- Preliminary SRF388 results indicate encouraging single-agent activity in a heavily pretreated population, including a confirmed partial response demonstrating 66% tumor shrinkage and symptomatic improvement in a patient with squamous cell non-small-cell lung carcinoma (NSCLC), whose disease was resistant to three prior regimens including chemotherapy and PD-1 blockade.
- In addition, 6 of 18 (33%) of evaluable patients experienced disease stabilization at eight weeks and five (28%) persisting beyond 16 weeks.
- SRF388 was well-tolerated at all doses tested, with no dose-limiting toxicity observed to date, with only low-grade treatment-related adverse events.
- Early data from combination cohorts point to SRF617's potential, including an unconfirmed partial response with an approximately 50% tumor shrinkage in a patient with pancreatic cancer receiving second-line treatment in combination with gemcitabine/albumin-bound paclitaxel (Abraxane).
- In addition, with SRF617 monotherapy, 7 of 19 evaluable patients (37%) achieved disease stabilization at eight weeks, with 4 (21%) persisting beyond 16 weeks.
- SRF617 was well-tolerated at all tested doses as a monotherapy and has a tolerability profile conducive to combination strategies.
- Price Action: SURF shares are down 3.42% at $8.75 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
